Extend your brand profile by curating daily news.

Viromed Medical AG Restructures Management Board for Next Growth Phase

By FisherVista•
Viromed Medical AG appoints Christian Strauch to its Management Board as founder Uwe Perbandt resigns, signaling a leadership shift to drive the company's next growth phase in cold plasma technology.
Viromed Medical AG Restructures Management Board for Next Growth Phase

Viromed Medical AG has announced a significant change to its Management Board, appointing Christian Strauch effective November 16, 2026, for a term lasting until October 31, 2029. Simultaneously, Uwe Perbandt, the company's founder and CEO, has resigned from his position effective December 31, 2026, citing personal reasons. The Supervisory Board approved the appointment, marking a transition in leadership as the company prepares for what it describes as an exciting next growth phase.

The change comes at a pivotal moment for Viromed, which specializes in cold plasma technology for medical applications. Dr. Thomas Gutschlag, Chairman of the Supervisory Board, emphasized that the transition occurs by mutual agreement with Perbandt, who shaped Viromed from its inception and developed it into an internationally leading enterprise in cold plasma technology. Gutschlag noted that with the recently achieved market readiness of Viromed's technology, the company stands at the threshold of a new growth phase, and he expressed confidence that Strauch's sales expertise makes him the ideal candidate to help shape it successfully.

Perbandt, reflecting on his tenure, stated that he built Viromed with passion and a dedicated team, expressing pride in their achievements. He highlighted the importance of cold plasma technology in helping people and saving lives, and he expressed confidence in handing over responsibility to Strauch, whom he described as a highly experienced successor and his preferred candidate. Perbandt will leave the Management Board with a clear conscience, ensuring continuity as the company moves forward.

Christian Strauch brings over twenty years of experience in building and scaling healthcare companies. He is currently Managing Director of pharmedix GmbH, a Viromed subsidiary. Strauch founded the mail-order pharmacy apo-rot, growing it to 450 employees and annual revenue of up to EUR 100 million, and oversaw the sale of its mail-order division to the Zur Rose Group or DocMorris (asset deal). As Managing Director of two DocMorris subsidiaries, he led the integration of acquisitions, initiated the acquisition of medpex, and restructured the group's procurement. Since 2020, he has been building the Vameda Group. He also founded two pharmaceutical wholesalers, which were sold to an investor group in 2024, and repositioned pharmedix GmbH as an omnichannel sales company, which Viromed acquired in 2024.

Viromed Medical AG, listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. The company serves a broad customer base in the DACH region and beyond and aims to further advance the use of cold plasma technology in medicine. The leadership change is expected to support these ambitions. For more information, visit the company's website at www.viromed-medical-ag.de. The original release is available on www.newmediawire.com.

FisherVista

FisherVista

@fishervista